Edition:
United Kingdom

Eagle Pharmaceuticals licenses Japanese rights for Bendamustine HCl


Wednesday, 20 Sep 2017 

Sept 20 (Reuters) - Eagle Pharmaceuticals Inc :Eagle Pharmaceuticals licenses Japanese rights for Bendamustine Hydrochloride ready-to-dilute and rapid infusion injection products to Symbio Pharmaceuticals Limited.$12.5 million upfront payment plus future potential milestones and royalty payments are part of deal​.Symbio has estimated that sales of Treakisym are estimated to grow to $90 million in 2018​.Company will also receive royalties on future net sales of licensed Bendamustine products.Symbio will target for approval of a product in 2020​. 

Company Quote

53.73
 --
18 Jun 2019